# Marc S. Sabatine

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marc-s-sabatine/

## Facts

| Field | Value |
| --- | --- |
| Citations | 123,372 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 146 |
| i10-index | 480 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5030057930 |
| ORCID iD | 0000-0002-0691-3359 |
| Works | 943 |

## Researcher papers

Showing 12 of 29.

- [2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-i-lipid/)
- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes](https://scholariq.org/papers/2014-aha-acc-guideline-for-the-management-of-patients-with-non-st-elevation/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Cytochrome P-450 Polymorphisms and Response to Clopidogrel](https://scholariq.org/papers/cytochrome-p-450-polymorphisms-and-response-to-clopidogrel/)
- [Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction](https://scholariq.org/papers/long-term-use-of-ticagrelor-in-patients-with-prior-myocardial-infarction/)
- [Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation](https://scholariq.org/papers/addition-of-clopidogrel-to-aspirin-and-fibrinolytic-therapy-for-myocardial/)
- [2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease](https://scholariq.org/papers/2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy/)
- [Myocardial infarction accelerates atherosclerosis](https://scholariq.org/papers/myocardial-infarction-accelerates-atherosclerosis/)
- [Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials](https://scholariq.org/papers/impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-2-inhibitors/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.